Page 3 - Jane Baj News Today : Breaking News, Live Updates & Top Stories | Vimarsana

PTC Therapeutics Announces Commercial Milestone Payment Following the Recent European Approval of Evrysdi™ News provided by Share this article Share this article SOUTH PLAINFIELD, N.J., April 1, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that a $20 million milestone payment was triggered by the first commercial sale of Evrysdi™ (risdiplam) in the European Union under its License and Collaboration Agreement with Roche. Approval for Evrysdi from the European Medicines Agency was received on March 30 for the treatment of spinal muscular atrophy (SMA) in adult...

Results from the Second Year of Evrysdi™ (risdiplam) Treatment Demonstrated Sustained Improvement of Motor Function in a Broad Range of SMA Patients - Sustained or improved motor function was observed with 24 months of treatment - - Patients and caregivers reported a greater ability to complete activities of daily livingwith increased independence - News provided by Share this article Share this article SOUTH PLAINFIELD, N.J., March 16, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced two-year data from Part 2 of the SUNFISH trial evaluating Evrysdi™ (risdiplam...

SOUTH PLAINFIELD, N.J., Feb. 26, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. , today announced that the European Medicines Agency Committee for Medicinal Products for Human Use has recommended the... | March 4, 2021

Positive Data from FIREFISH Study of Evrysdi™ (risdiplam) in Infants with Type 1 Spinal Muscular Atrophy Published in The New England Journal of Medicine -- Results found that patients treated with Evrysdi at 12 months demonstrated significant improvements in survival and developmental milestones -- -- The U.S. Food and Drug Administration approved Evrysdi in August 2020 as the first and only at home SMA treatment with proven efficacy in adults, children and infants 2 months and older -- News provided by Share this article Share this article SOUTH PLAINFIELD, N.J., Feb. 24, 2021 /PRNewswire...

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its fourth quarter and...